NEWS
The information contained in each news post on this page was factually accurate on the date it was issued and posted.
Jefferies Healthcare Conference 2022 – Presentation
2022 ASCO Annual Meeting – Abstract
Abstract Number TPS5622 STRO-002-GM2: A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination with Bevacizumab in Patients With Advanced Epithelial Ovarian Cancer...
Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., June 3, 2022 – Sutro Biopharma, Inc. (“Sutro” or the “Company”) (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create...
Bill Newell, CEO Interviewed by Dr. Michelle McMurry-Heath on I Am Bio Podcast, Episode 73 – “Investors Become Goldilocks in a Bear Market”
Episode Summary Current market trends have put investors in a “flight-to-safety” mentality, especially when it comes to biotech companies. What does this mean for getting biotech innovations to the marketplace? This episode explores the daunting challenge of raising...
Sutro Biopharma Participated in a Clinical Trial, “Egg-Derived Anti-SARS-CoV-2 Immunoglobulin Y (IgY) With Broad Variant Activity as Intranasal Prophylaxis Against COVID-19” Published by Frontiers in Immunology
Clinical Trial Article Egg-Derived Anti-SARS-CoV-2 Immunoglobulin Y (IgY) With Broad Variant Activity as Intranasal Prophylaxis Against COVID-19 https://www.frontiersin.org/articles/10.3389/fimmu.2022.899617/full Frontiers in Immunology Published: 01 June 2022
Sutro Biopharma to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., June 2, 2022 – Sutro Biopharma, Inc. (“Sutro” or the “Company”) (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create...
Sutro Biopharma Reports First Quarter 2022 Financial Results, Business Highlights, and Anticipated Milestones
- Cash, cash equivalents and marketable securities totaled $192.1 million as of March 31, 2022, with projected cash runway into the second half of 2023 - - Meetings with regulatory agencies for STRO-002 are planned for mid-year 2022 and near-final dose expansion data...
Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., April 29, 2022 – Sutro Biopharma, Inc. (“Sutro” or the “Company”) (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to...
21st Annual Needham Virtual Healthcare Conference – Presentation
Kristin Bedard, Ph.D., VP of Discovery interviewed by Gail Dutton, BioSpace in a recent article, “Sutro Delivers Evidence of One-Two Immunogenic Punch at AACR”
Sutro Delivers Evidence of One-Two Immunogenic Punch at AACR https://www.biospace.com/article/sutro-delivers-evidence-of-one-two-immunogenic-punch-at-tumors-at-aacr/ Gail Dutton, BioSpace April 11, 2022 Cancer therapies are, increasingly, throwing one-two punches at...